STOCK TITAN

Delcath Systems (DCTH) Stock Price, News & Analysis

DCTH NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
16 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+35.8% close of November 9, 2026
1-year change
+129.4% closing prices, November 20, 2025 to November 20, 2026
1-month change
+27.3% closing prices, October 20, 2026 to November 20, 2026

Company Description

Delcath Systems Inc (Nasdaq: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. Operating in the surgical and medical instrument manufacturing industry within the broader manufacturing sector, Delcath develops and commercializes proprietary drug–device technologies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects.

The company’s business centers on its hepatic delivery technologies, which are used in a procedure known as percutaneous hepatic perfusion (PHP). According to company disclosures, Delcath operates through a single reportable segment that encompasses the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific liver-related conditions. The company conducts business in the United States and Europe.

Core products and technology

Delcath’s proprietary products are HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan. Both are designed to administer high-dose melphalan chemotherapy to the liver during a PHP procedure while controlling systemic exposure.

  • HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System): In the United States, HEPZATO KIT is treated as a combination drug and device product and is regulated and approved for sale as a drug by the U.S. Food and Drug Administration (FDA. The kit combines the chemotherapeutic drug melphalan with Delcath’s proprietary Hepatic Delivery System (HDS).
  • CHEMOSAT Hepatic Delivery System (HDS) for Melphalan: In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT. It has been used at major medical centers in percutaneous hepatic perfusion procedures to treat a range of cancers of the liver.

The HDS component is used to isolate hepatic venous blood from the systemic circulation while simultaneously filtrating the hepatic venous blood during melphalan infusion and washout. Company materials state that this approach results in loco-regional delivery of a relatively high melphalan dose that can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduced systemic exposure.

Therapeutic focus and indications

Delcath’s primary therapeutic focus is on metastatic uveal melanoma (mUM) and other cancers involving the liver. The company describes itself as focused on the treatment of primary and metastatic liver cancers, with a particular emphasis on liver-dominant metastatic disease.

In the United States, HEPZATO KIT is approved as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. The company notes that full prescribing information, including a boxed warning, applies to the product.

In Europe, CHEMOSAT has been used in PHP procedures at major medical centers to treat a wide range of cancers of the liver. Published data cited in company news releases describe use of CHEMOSAT in liver-dominant metastatic uveal melanoma and other liver metastases, with studies examining survival outcomes, disease control, and the role of repeated PHP cycles.

Clinical evidence and research activity

Delcath’s technologies are supported by a body of clinical and real-world evidence referenced in its public communications. The company highlights:

  • A Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma, which led to the FDA approval of HEPZATO. Subgroup analyses of this study have been published, assessing efficacy and safety across factors such as age, sex, geographic region, tumor burden, extent of liver involvement, extrahepatic lesions, baseline LDH, and prior therapies.
  • The CHOPIN Phase 2 trial, sponsored by Leiden University Medical Center, evaluating CHEMOSAT with the immune checkpoint inhibitors ipilimumab and nivolumab in metastatic uveal melanoma. Company disclosures report a significant improvement in one-year progression-free survival for the combination versus CHEMOSAT alone.
  • A 10-year single-center experience from Asklepios Hospital Barmbek in Hamburg, Germany, using CHEMOSAT for liver-dominant metastatic uveal melanoma, reporting safety and efficacy outcomes over multiple PHP procedures.
  • A retrospective analysis from the University of Tübingen examining long-term survivors with liver metastases from uveal melanoma, which underscores the potential benefits of early use of liver-directed therapies, including PHP, in achieving long-term survival.
  • An expert narrative review in the Journal of Vascular and Interventional Radiology summarizing the rationale, technique, patient selection, clinical outcomes, and research directions for PHP with melphalan using HEPZATO KIT, and emphasizing its role as an FDA-approved liver-directed therapy for unresectable hepatic metastases from uveal melanoma with limited extrahepatic disease.

These publications and analyses, as described in Delcath’s news releases, collectively present data on objective response rates, progression-free survival, overall survival, disease control rates, safety profiles, and the impact of tumor burden and treatment sequencing on outcomes in metastatic uveal melanoma and liver-dominant disease.

Geographic footprint and regulatory status

Delcath reports that it operates its business in the United States and Europe. In the U.S., HEPZATO KIT is FDA-approved and regulated as a drug–device combination product. In Europe, the CHEMOSAT Hepatic Delivery System is regulated as a Class III medical device and approved for sale under the CHEMOSAT trade name.

The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Capital Market under the symbol DCTH, as confirmed in multiple Form 8-K filings. These filings also show that Delcath is incorporated in Delaware and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC).

Corporate and financial reporting

Delcath communicates its financial and operational performance through press releases and SEC filings, including Form 8-K reports on quarterly results, preliminary financial updates, and other material events. Recent disclosures describe product revenue derived from HEPZATO KIT in the United States and CHEMOSAT in Europe, as well as information on gross margins, operating expenses, and cash and investment balances. The company also reports on non-GAAP measures such as adjusted EBITDA and explains the rationale for presenting these metrics alongside GAAP results.

In addition, Delcath has disclosed the authorization of a share repurchase program under which the board of directors approved the repurchase of up to a specified dollar amount of outstanding common stock, subject to market conditions. The company has also reported equity inducement grants under a stock incentive plan, consistent with Nasdaq listing rules.

Governance and regulatory disclosures

Delcath’s SEC filings indicate ongoing corporate governance activity, including amendments and restatements of its bylaws. An 8-K filing describes updates to advance notice provisions for stockholder nominations and proposals, officer and chairperson election provisions, indemnification rights for directors, officers and other agents, and various administrative and clarifying changes.

The company’s filings also include standard forward-looking statement disclosures under the Private Securities Litigation Reform Act of 1995, noting that certain statements about financial outlook, clinical development, and business plans are subject to risks and uncertainties.

Position within the medical device and oncology landscape

Within the broader manufacturing sector, Delcath is classified in surgical and medical instrument manufacturing, with a specialized focus on interventional oncology and liver-directed therapies. Its business model centers on proprietary hepatic delivery systems and associated drug–device combinations used in PHP procedures for patients with liver metastases, particularly metastatic uveal melanoma.

By concentrating on loco-regional chemotherapy delivery to the liver and supporting this approach with clinical trials, retrospective analyses, and expert reviews, Delcath positions its technologies as options for managing liver-dominant metastatic disease in settings where systemic exposure to chemotherapy must be controlled. The company’s disclosures emphasize the potential for high-dose melphalan delivery with controlled systemic exposure, the role of PHP in multimodal treatment strategies, and the use of its products at specialized centers in the U.S. and Europe.

Stock Performance

$18.50
-1.54%
-0.29
After hoursChange vs the $18.79 closeLast updated: at
+129.4%
Performance 1 year
$643.6M
34.8M
Shares outstanding As of October 30, 2026.

Delcath Systems (DCTH) closed at $18.79 on November 20, 2026. Over the past 12 months, the price has gained 129.4%.

See what a $1,000 investment in DCTH would be worth today

Average down calculator for DCTH

DCTH Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Delcath Systems has 10 recent news articles, with the latest published on . Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, conferences, earnings date. View all DCTH news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
22,500
Shares Sold
2
Transactions
Most Recent Transaction
Martell Bridget A (Director) sold 22,500 shares at an average of $21.71 on November 12, 2026

Insider selling at Delcath Systems over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Delcath Systems generated $85.2M in revenue in FY2025, retaining a 86.2% gross margin, operating income reached $660K (0.8% operating margin), and net income was $2.7M, reflecting a 3.2% net profit margin. Diluted earnings per share stood at $0.07. The company generated $22.5M in operating cash flow. The current ratio was 10.92, measuring current assets divided by current liabilities.

$85.2M
Revenue (FY2025)
$2.7M
Net Income (FY2025)
$22.5M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Regulatory

Cholangiocarcinoma IND filing

Planned investigational new drug (IND) application for cholangiocarcinoma in early 2027 (Jan 1–Apr 30, 2027).
JAN
02
January 2, 2027 Corporate

RSU vesting — 1st installment

One-third of 36,250 RSUs vests; subject to continued employment.
MAY
01
May 1, 2027 Corporate

RSU vesting (one-third)

One-third of 24,500 RSUs vests on first anniversary; under 2023 Inducement Plan; subject to continued employment.
SEP
01
September 1, 2027 Corporate

RSU first vesting

One‑third of 34,000 RSUs granted Sept 1, 2026 vest for four employees on 2027-09-01 under 2023 Inducement Plan.
NOV
17
November 17, 2027 Corporate

RSU first vesting

One-third of 21,250 RSUs (7,083.33 shares) vest on the first anniversary of the grant; subject to continued employment.
JAN
02
January 2, 2028 Corporate

RSU vesting — 2nd installment

One-third of 36,250 RSUs vests; subject to continued employment.
MAY
01
May 1, 2028 Corporate

RSU vesting (second tranche)

Second one-third of 24,500 RSUs vests on second anniversary; under 2023 Inducement Plan; subject to continued employment.
SEP
01
September 1, 2028 Corporate

RSU second vesting

One‑third of 34,000 RSUs granted Sept 1, 2026 vest for four employees on 2028-09-01 under 2023 Inducement Plan.
YEAR
2028
2028 Clinical

Overall survival data

Expected overall survival data from global Phase 2 HEPZATO trial
NOV
17
November 17, 2028 Corporate

RSU second vesting

One-half of the remaining RSUs vest (approx. 7,083.33 shares) on the second anniversary; subject to continued employment.
Q4
2028
Q4 2028 Clinical

Primary endpoint results

YEAR
2029
2029 Clinical

Overall survival results

JAN
02
January 2, 2029 Corporate

RSU vesting — 3rd installment

One-third of 36,250 RSUs vests; subject to continued employment.
MAY
01
May 1, 2029 Corporate

RSU vesting (final tranche)

Final one-third of 24,500 RSUs vests on third anniversary; under 2023 Inducement Plan; subject to continued employment.
JUL
01
July 1, 2029 Corporate

RSU vesting completion

Final vesting of 17,000 RSUs granted July 1, 2026 under 2023 Inducement Plan; subject to continued employment.
SEP
01
September 1, 2029 Corporate

RSU final vesting

Final one‑third of 34,000 RSUs granted Sept 1, 2026 vests for four employees on 2029-09-01 under 2023 Inducement Plan.
NOV
17
November 17, 2029 Corporate

RSU final vesting

Final tranche of RSUs vests on the third anniversary (approx. 7,083.34 shares); remaining shares subject to continued employment.
OCT
31
October 31, 2035 Corporate

Option expiration

10-year term expires for options granted on Oct 31, 2025

Delcath Systems has 18 upcoming scheduled events. The next event, "Cholangiocarcinoma IND filing", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the DCTH stock price.

Short Interest History

Last 12 Months

Short interest in Delcath Systems (DCTH) currently stands at 1.8 million shares, down 5.7% from the previous reporting period, representing 5.4% of the float. Since November 2025, short interest has decreased by 59.0%.

Days to Cover History

Last 12 Months

Days to cover for Delcath Systems (DCTH) currently stands at 5.7 days, down 8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 22.9%. Across the settlements charted above, it has ranged from 2.3 to 13.8 days.

DCTH Company Profile & Sector Positioning

Delcath Systems (DCTH) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing DCTH often look at related companies in the same sector, including Beta Bionics, Inc. (BBNX), Bioventus Inc. (BVS), Tactile Systems Technology, Inc. (TCMD), Sight Sciences, Inc. (SGHT), and Varex Imaging Corporation (VREX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DCTH's relative position within its industry.

Frequently Asked Questions

The current stock price of Delcath Systems (DCTH) is $18.50 in after-hours trading as of November 20, 2026.

The market cap of Delcath Systems (DCTH) is approximately $643.6M. Learn more about what market capitalization means .

The FY2025 revenue of Delcath Systems (DCTH) is $85.2M, from its most recent completed fiscal year.

The FY2025 net income of Delcath Systems (DCTH) is $2.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Delcath Systems (DCTH) is $0.07 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Delcath Systems (DCTH) is $22.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Delcath Systems (DCTH) is 3.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Delcath Systems (DCTH) is 0.8% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Delcath Systems (DCTH) is 86.2% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Delcath Systems (DCTH), current assets divided by current liabilities, was 10.92 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Delcath Systems (DCTH) is $73.4M for FY2025, its most recent completed fiscal year.

The operating income of Delcath Systems (DCTH) is $660K for FY2025, its most recent completed fiscal year. Learn about operating income.